Staphylococcus aureus antigenic epitopes (S. aureus epitopes)

Staphylococcus aureus antigenic epitopes are specific molecular structures on the surface or secreted by the bacterium that are recognized by the host immune system. These epitopes include surface proteins like Clumping factor A (ClfA) and Iron-regulated surface determinant B (IsdB), as well as secreted toxins such as Alpha-hemolysin (Hla) and Panton-Valentine Leukocidin (PVL) (Bagnoli et al., 2012, PMID: 22233677). In the context of drug development, these epitopes serve as the primary targets for vaccines and monoclonal antibodies designed to prevent or treat S. aureus infections. By targeting these sites, therapeutics aim to neutralize virulence factors, inhibit bacterial adhesion to host tissues, or enhance opsonophagocytic killing by immune cells (François et al., 2021, PMID: 33441400). These epitopes are critical for the pathogen's ability to colonize the host, evade immune detection, and cause tissue damage. Despite numerous attempts to target these epitopes, many candidates have failed in late-stage clinical trials, highlighting the challenge of the pathogen's redundant virulence mechanisms and sophisticated immune evasion strategies (Fowler et al., 2013, PMID: 23543513). Current research focuses on multi-component vaccines and monoclonal antibody cocktails to address the diversity of S. aureus strains and their varied antigenic profiles. The identification of conserved and protective epitopes remains a cornerstone of efforts to combat antibiotic-resistant strains like MRSA.

Other names

Staphylococcus aureus antigensStaphylococcal surface antigensStaphylococcal epitopes

Neutralization of bacterial toxins, inhibition of bacterial adhesion, and enhancement of opsonophagocytosis.